Key result
Tailored antiplatelet de-escalation reduces bleeding without compromising ischemic protection in East Asian ACS patients.
Why the study?
East Asian patients are underrepresented in trials establishing standard DAPT regimens, and their lower ischemic but higher bleeding risk raises concerns about applying Western DAPT strategies.
May support tailored de-escalation to reduce bleeding in East Asian ACS; hypothesis-generating and requires randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in Acute coronary syndrome. Tailored antiplatelet therapy (short-term DAPT, de-escalation, reduced-dose prasugrel) vs. Standard 12-month potent DAPT was evaluated. Tailored antiplatelet strategies, including short-term DAPT followed by P2Y12 inhibitor monotherapy or de-escalation, reduce bleeding risk without compromising ischemic protection in East Asian patients with ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: